Concert Pharmaceuticals, Inc. (CNCE) Names Thomas Auchincloss To Board Of Directors And Chair Of The Audit Committee

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) announced today that Thomas G. Auchincloss, Jr. will join its Board of Directors and serve as the independent chair of the Board's Audit Committee, effective immediately. Mr. Auchincloss replaces Helmut Schühsler as Chair of the Audit Committee. Dr. Schühsler will remain a member of Concert's Board of Directors.

Suggested Articles

A TGen-led research team found that increased activity of the gene AEBP1 drives severe liver fibrosis in nonalcoholic steatohepatitis.

Days after announcing its R&D chief was stepping down, Gilead announced it will be buying a few of Novartis’ unwanted early-stage infection assets.

Mallinckrodt is teaming up with Silence Therapeutics to develop an RNAi program aimed at a group of proteins that play a part in promoting inflammation.